共 16 条
Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation
被引:49
作者:
Cummins, N. W.
[1
,2
]
Deziel, P. J.
[2
]
Abraham, R. S.
[3
]
Razonable, R. R.
[1
,2
]
机构:
[1] Mayo Clin, Coll Med, Dept Internal Med, Div Infect Dis, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, William J von Liebig Transplant Ctr, Rochester, MN 55905 USA
[3] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Cellular & Mol Immunol Lab, Rochester, MN 55905 USA
关键词:
cytomegalovirus;
immunity;
outcome;
kidney transplantation;
T cells;
CD8+;
late onset;
LIVER-TRANSPLANTATION;
ANTIVIRAL PROPHYLAXIS;
RECIPIENTS;
OUTCOMES;
RISK;
INFECTION;
MORTALITY;
D O I:
10.1111/j.1399-3062.2008.00344.x
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
N.W. Cummins, P.J. Deziel, R.S. Abraham, R.R. Razonable. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation.Transpl Infect Dis 2009: 11: 20-27. All rights reserved Cytomegalovirus (CMV) is a major cause of morbidity and mortality among transplant recipients. The routine use of anti-CMV prophylaxis has modified the epidemiology of post-transplant CMV infection by delaying the onset of clinical disease. While the majority of delayed-onset CMV disease still occurs during the first year after transplant, reports of late-onset CMV disease presenting many years after transplantation are increasing. Here, we describe 2 CMV-seropositive transplant recipients who presented with late-onset CMV disease at 8 and 11 years after transplantation. To determine whether CMV disease occurring at a very late period after transplantation is related to immune competence, we assessed global and CMV-specific cellular immunity by evaluating the activation capability of CD8+ T cells to a mitogenic stimulus and by quantitative and functional analysis (as assessed by intracellular cytokine production and degranulation) of CMV-specific CD8+ T cells. In both patients, we demonstrated the absence or marked deficiency of CMV-specific T-cell immunity despite CMV seropositivity, and in one patient, a partial defect in the immune response to phorbol myristate acetate and ionomycin suggesting impaired global immune competence. Hence, our data suggest that late-onset CMV disease occurring many years after transplantation remains related to defects in the immune competence of patients. Measurement of CMV-specific cellular immune competence may therefore provide an additional tool to screen for patients at high risk of developing late-onset CMV disease. The clinical utility of this assay, however, will need to be evaluated in larger prospective studies.
引用
收藏
页码:20 / 27
页数:8
相关论文